3 citations · 5 across the 6 of their papers we have counts for
1 paper · 1 filter
Moritz Fabian Danzer, Kaspar Rufibach, Jan Beyersmann +1
In oncological clinical trials, overall survival (OS) is the gold-standard endpoint, but long follow-up and treatment switching can delay or dilute detectable effects. Progression-…